EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity

Hao Wu, Jiena Liu, Xing-Hua Zhang, Shengye Jin, Ping Li, Huidi Liu, Liuying Zhao, Jianyu Wang, Shilu Zhao, Hong-Da Tian, Jin-Ru Lai, Yi Hao und 5 weitere

Drug Resistance Updates · 2025-05 · 80 · 101222

DOI: 10.1016/j.drup.2025.101222 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2025-05. Verfasst von Hao Wu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Heilongjiang Clinical Research Center for Breast Cancer, Harbin Medical University Cancer Hospital, Harbin, China; Genomics Research Center, State Ke…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Breast Neoplasms, Lignans, Flax. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with breast cancer (BC) who benefit from the PD-1/PD-L1 inhibitor (PDi) is limited, necessitating novel strategies to improve immunotherapy efficacy of BC. Here we aimed to investigate the inhibitory effects of flaxseed lignans (FL) on the biological behaviors of BC and evaluate the roles of FL in enhancing the anticancer effects of PDi. METHODS: HPLC was used to detect the content of enterolactone (ENL), the bacterial transformation product of FL. Transcript sequencing was performed and identified CD38 as a downstream target gene of ENL. CD38-overexpressing cells were constructed and cell proliferation, colony formation, wound healing and transwell assays were used to assess the function of ENL/CD38 axis on BC cells in vitro. Multiplexed immunohistochemistry (mIHC) and CyTOF were used to detect the changes of the tumor immune microenvironment (TIM). 16S rDNA sequencing was used to explore the changes of gut microbiota in mice. A series of in vivo experiments were conducted to investigate the anticancer effects and mechanisms of FL and PDi. RESULTS: FL was converted to ENL by gut microbiota and FL administration inhibited the progression of BC. ENL inhibited the malignant behaviors of BC by downregulating CD38, a key gene associated with immunosuppression and PD-1/PD-L1 blockade resistance. The mIHC assay revealed that FL administration enhanced CD3+, CD4+ and CD8+ cells and reduced F4/80+ cells in TIM. CyTOF confirmed the regulatory effects of FL and FL in combination with PDi (FLcPDi) on TIM. In addition, 16S rDNA analysis demonstrated that FLcPDi treatment significantly elevated the abundance of Akkermansia and, importantly, Akkermansia administration enhanced the response to PDi in mice treated with antibiotics. CONCLUSIONS: The FL/ENL/CD38 axis inhibited BC progression. FL enhanced the anticancer effects of PDi by modulating gut microbiota and host immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeBreast NeoplasmsLignansFlaxImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsAnimalsFemaleMiceHumansProgrammed Cell Death 1 ReceptorTumor MicroenvironmentCell ProliferationCell Line, TumorB7-H1 Antigen4-ButyrolactoneMice, Inbred BALB CXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Breast cancerCombined immunotherapyENLFlaxseed lignansGut microbiota

Substanzen

LignansProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsB7-H1 AntigenPDCD1 protein, human4-ButyrolactoneCD274 protein, human2,3-bis(3'-hydroxybenzyl)butyrolactone

Autor:innen und Institutionen

  • Heilongjiang Clinical Research Center for Breast Cancer, Harbin Medical University Cancer Hospital, Harbin, China; Genomics Research Center, State Key Laboratory of Biomedicine-Pharmaceutics of China, College of Pharmac…
  • Heilongjiang Clinical Research Center for Breast Cancer, Harbin Medical University Cancer Hospital, Harbin, China; Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China. Electronic addre…
  • Genomics Research Center, State Key Laboratory of Biomedicine-Pharmaceutics of China, College of Pharmacy, Harbin Medical University, Harbin, China; Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang…
  • Heilongjiang Clinical Research Center for Breast Cancer, Harbin Medical University Cancer Hospital, Harbin, China; Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
  • The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China.
  • Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wu, H., Liu, J., Zhang, X. H., Jin, S., Li, P., Liu, H., Zhao, L., Wang, J., Zhao, S., Tian, H. D., Lai, J. R., Hao, Y., Liu, G. R., Hou, K., Yan, M., Liu, S. L., & Pang, D. (2025). The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101222

Vancouver

Wu H, Liu J, Zhang XH, Jin S, Li P, Liu H, et al. The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity. Drug Resistance Updates. 2025. doi:10.1016/j.drup.2025.101222

BibTeX
@article{Wu2025,
  author = {Wu, Hao and Liu, Jiena and Zhang, Xing-Hua and Jin, Shengye and Li, Ping and Liu, Huidi and Zhao, Liuying and Wang, Jianyu and Zhao, Shilu and Tian, Hong-Da and Lai, Jin-Ru and Hao, Yi and Liu, Gui-Rong and Hou, Kaijian and Yan, Meisi and Liu, Shu-Lin and Pang, Da},
  title = {The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity},
  journal = {Drug Resistance Updates},
  year = {2025},
  doi = {10.1016/j.drup.2025.101222}
}
Kostenlos starten →